Author Page for Jin-Bo Gou

Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial

Number of pages: 26 Posted: 04 Jan 2022

Nanjing Medical University, Academy of Military Medical Sciences - Institute of Biotechnology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Chinese Center for Disease Control and Prevention (China CDC) - NHC Key Laboratory of Biosafety, Donghai County Center for Disease Control and Prevention, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, CanSino Biologics Inc., Donghai County Center for Disease Control and Prevention, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, CanSino Biologics Inc., Nanjing Vazyme Biotech Co., Ltd., Nanjing Medical University - School of Public Health, Southeast University - School of Public Health, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, CanSino Biologics Inc., Chinese Center for Disease Control and Prevention (China CDC) - NHC Key Laboratory of Biosafety, Academy of Military Medical Sciences - Institute of Biotechnology and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology

Downloads 456 (157,043)

Citation 1

Abstract:

2.

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

Number of pages: 25 Posted: 15 Feb 2023

Jundong Wu, Jing-Xin Li, Jian Liu, Haomeng Wang, Guanghui Zhou, Jin Li, Dou Wu, Xiang Chen, Yan Feng, Ying Wang, Xiaoyuan Qi, Xue Wang, Xiaomin Ma, Jin-Bo Gou, Tieliang Ma, Xiaoyun Yang, Lifeng Xu, Peng Wan, Tao Zhu, Zhongfang Wang and Feng-Cai Zhu

Yixing People's Hospital, Nanjing Medical University, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, Yixing People's Hospital, CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Laboratory, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology

Downloads 227 (336,244)

Abstract:

3.

Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial

Number of pages: 24 Posted: 30 Dec 2022

Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Southeast University - School of Public Health, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Donghai County Center for Disease Control and Prevention, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Donghai County Center for Disease Control and Prevention, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Lianshui Center for Disease Control and Prevention, CanSino Biologics Inc., Nanjing Vazyme Biotech Co., Ltd., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Nanjing Medical University - School of Public Health, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Southeast University - School of Public Health, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Lianshui Center for Disease Control and Prevention, CanSino Biologics Inc., Academy of Military Medical Sciences - Institute of Biotechnology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology and Nanjing Medical University

Downloads 156 (477,517)

Abstract:

4.

Safety, Immunogenicity, and Efficacy of Recombinant COVID-19 Inhalation Vaccine (Adenovirus Type 5 Vector) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections: An Observer-Blinded, Randomised, Phase 3, Non-Inferiority Trial

Number of pages: 31 Posted: 18 Mar 2024

Institute for Clinical Research, CanSino Biologics Inc., Hospital Kuala Lumpur, Selayang Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Institute for Clinical Research, Academy of Military Medical Sciences - Institute of Biotechnology, Hospital Kuala Lumpur, Selayang Hospital, Institute for Clinical Research, Hospital Kuala Lumpur, CanSino Biologics Inc., University of Malaya (UM), Academy of Military Medical Sciences - Institute of Biotechnology, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., CanSino Biologics Inc., Clin Research Private Enterprise, CanSino Biologics Inc., Institute for Clinical Research and Independent

Downloads 124 (580,653)

Citation 1

Abstract:

5.

Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label Trial

Number of pages: 25 Posted: 07 Apr 2023

Jing-Xin Li, Li-Hua Hou, Jin-Bo Gou, Si-Yue Jia, Zun-Dong Yin, Rong Tang, Shi-Po Wu, Fu-Zhen Wang, Zhe Zhang, Hong-Xing Pan, Li Zhang, Jia-Wei Xu, Zhi-Hang Peng, Ji-Hai Tang, Qing Wang, Qing Xu, Yan Zheng, Tao Huang, Tao Li, Shu-Jun Liu, Cang-Ning Wang, Tao Zhu, Hong-Bing Shen, Wei Chen and Feng-Cai Zhu

Nanjing Medical University, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Chinese Center for Disease Control and Prevention (China CDC) - National Immunization Program, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Academy of Military Medical Sciences - Institute of Biotechnology, Chinese Center for Disease Control and Prevention (China CDC), Academy of Military Medical Sciences - Institute of Biotechnology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Government of the People's Republic of China - Center of Disease Control and Prevention, Chongqing Center for Disease Control and Prevention, Nanjing Medical University - School of Public Health, Anhui Provincial Center for Disease Control and Prevention, Chongqing Center for Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Yunan Provincial Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Anhui Provincial Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Yunan Provincial Center for Disease Control and Prevention, CanSino Biologics Inc., Nanjing Medical University - Department of Epidemiology and Biostatistics, Academy of Military Medical Sciences - Institute of Biotechnology and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology

Downloads 116 (613,149)

Abstract:

6.

Safety and Immunogenicity of Heterologous and Homologous Boosting with Orally Aerosolized or Intramuscular Ad5-nCoV and Inactivated Vaccines in Children and Adolescents: A Randomized, Open-Label, Parallel Controlled, Single-Center Study

Number of pages: 20 Posted: 20 Dec 2022

Tao Huang, Sheng Zhang, De-Fang Dai, Bu-Sen Wang, Lu Zhuang, Hai-Tao Huang, Zhongfang Wang, Jun-Shi Zhao, Qiu-Ping Li, Shi-Po Wu, Xue Wang, Wen-Dan Zhang, Zheng-Hao Zhao, Hao Li, Jin-Bo Gou, Li-Hua Hou, Li-Dong Gao and Zhi-Chun Feng

Hunan Provincial Center for Disease Control and Prevention, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Hunan Provincial Center for Disease Control and Prevention, Academy of Military Medical Sciences - Institute of Biotechnology, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Hunan Provincial Center for Disease Control and Prevention, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Beijing Institute of Biotechnology, CanSino Biologics Inc., CanSino Biologics Inc., Academy of Military Medical Sciences - Institute of Biotechnology, Hunan Provincial Center for Disease Control and Prevention and Southern Medical University - Neonatal Intensive Care Unit

Downloads 108 (649,907)

Abstract:

7.

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double blinded phase 3 trial

Number of pages: 34 Posted: 01 Oct 2025

Adora Rooyakkers, Lingyun Ye, Pedro E. Cahn, Guillermo M. Ruiz-Palacios, Aamer Ikram, Fernando Lanas, Sergio Munoz, Omar Sued, Dmitry Lioznov, Vitalina Dzutseva, Ghazala Parveen, Tatyana Zubkova, Jing-Xin Li, Joanne Marie Langley, Ruijie Wang, Luis Barreto, Jin-Bo Gou, Tao Zhu, Carrie A. Whittle and Scott A. Halperin

affiliation not provided to SSRN, Dalhousie University, Fundación Huésped, affiliation not provided to SSRN, National Institutes of Health, Chak Shahzad, Universidad de la Frontera, Independent, affiliation not provided to SSRN, Ministry of Health of the Russian Federation, Novosibirsk State University, affiliation not provided to SSRN, Ministry of Health of the Russian Federation, Nanjing Medical University, Dalhousie University, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Dalhousie University and Dalhousie University

Downloads 64 (924,743)

Jin-Bo Gou

CanSino Biologics Inc.

7

1,251

2

Scholarly Papers (7)

Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial

Abstract:

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

Abstract:

Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial

Abstract:

Safety, Immunogenicity, and Efficacy of Recombinant COVID-19 Inhalation Vaccine (Adenovirus Type 5 Vector) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections: An Observer-Blinded, Randomised, Phase 3, Non-Inferiority Trial

Abstract:

Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label Trial

Abstract:

Safety and Immunogenicity of Heterologous and Homologous Boosting with Orally Aerosolized or Intramuscular Ad5-nCoV and Inactivated Vaccines in Children and Adolescents: A Randomized, Open-Label, Parallel Controlled, Single-Center Study

Abstract:

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double blinded phase 3 trial

Abstract: